Number of events: This text provides information about the number of events in a study conducted on two groups: one group receiving Rosuva 20 mg and the other receiving a placebo of 20 mg.
Hazard Ratio: The hazard ratio (HR) and its corresponding 95% confidence interval (CI) are also presented for each endpoint. The hazard ratio compares the risk of experiencing an event between the two groups.
Endpoints: The text lists several endpoints and their corresponding results in terms of number of events, event rates per 1000-patient years, and hazard ratios.
Primary endpoint (MCE): The primary endpoint refers to a certain measure of clinical effectiveness (MCE) that was being evaluated in the study. The text provides the number of events and event rates for this endpoint in both the Rosuva 20 mg and Placebo 20 mg groups. The hazard ratio for the primary endpoint is also included.
Cardiovascular death: This endpoint focuses on the occurrence of cardiovascular deaths in the two groups. The text provides the number of events and event rates for this endpoint as well as the hazard ratio.
Nonfatal Stroke: The text contains information about nonfatal strokes, including the number of events, event rates, and hazard ratio.
Nonfatal MI: The number of nonfatal myocardial infarctions (MI) is provided for both groups, along with their corresponding event rates and hazard ratio.
Hospitalized unstable Angina: The text mentions the number of events, event rates, and hazard ratio for hospitalized cases of unstable angina in the study.
Arterial revascularization: Information regarding arterial revascularization events, including number of events, event rates, and hazard ratio, is also given.
Please note that the provided description is based on the available text and may not cover all aspects of the study or provide an in-depth analysis.*
